Dasatinib

Catalog No.S1021

Dasatinib is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM in cell-free assays, respectively.

Price Stock Quantity  
USD 140 In stock
USD 147 In stock
USD 370 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

Dasatinib Chemical Structure

Dasatinib Chemical Structure
Molecular Weight: 488.01

Validation & Quality Control

Cited by 62 publications:

10 customer reviews :

Quality Control & MSDS

Related Compound Libraries

Src Inhibitors with Unique Features

  • Pan Src Inhibitor

    Saracatinib (AZD0530) Pan-Src inhibitor, IC50=2.7-11 nM for c-Src/c-Yes/Fyn/Lyn/Blk/Fgr/Lck.

  • FDA-approved Src Inhibitor

    Bosutinib (SKI-606) Approved by FDA for Ph+ chronic myelogenous leukemia (CML).

  • Newest Src Inhibitor

    PP1 Potent and selective Src inhibitor for Lck/Fyn with IC50 of 5 nM/ 6 nM.

  • Classic Src Inhibitor

    KX2-391 The first clinical Src inhibitor (peptidomimetic class) that targets the peptide substrate site of Src, with GI50 of 9-60 nM in cancer cell lines.

Product Information

  • Compare Src Inhibitors
    Compare Src Products
  • Research Area
  • Combination Therapy
    Combination Therapy

Product Description

Biological Activity

Description Dasatinib is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM in cell-free assays, respectively.
Targets Abl [1]
(Cell-free assay)
Src [1]
(Cell-free assay)
c-Kit (D816V) [2]
(Cell-free assay)
c-Kit (wt) [2]
(Cell-free assay)
IC50 0.6 nM 0.8 nM 37 nM 79 nM
In vitro Dasatinib is more effective than imatinib in inhibiting the proliferation of Ba/F3 cells expressing wild-type Bcr-Abl and Bcr-Abl mutants, with the exception of T315I. Dasatinib has a two-log (∼325-fold) increased potency relative to imatinib. Dasatinib potently inhibits wild-type Abl kinase and all mutants except T315I over a narrow range. Dasatinib directly targets wild-type and mutant Abl kinase domains and inhibits autophosphorylation and substrate phosphorylation in a concentration-dependent manner. Dasatinib displays 325-fold greater potency compared with imatinib against cells expressing wild-type Bcr-Abl. [1] The percent of colonies of TgE bone marrow cells are decreased from 100% in untreated wells to 4.12% in Dasatinib treated wells. In the presence of Dasatinib, the difference in the percentage of colonies formed by WT and TgE bone marrow cells is statistically significant. Expression of LMP2A is able to promote B lymphocyte survival and proliferation, which can be inhibited by targeting Lyn and/or c-Abl kinases through Dasatinib. [3] Dasatinib treatment inhibits Src signaling, decreases growth, and induces cell cycle arrest and apoptosis in a subset of thyroid cancer cells. Treatment with increasing doses of Dasatinib (0.019 μM to 1.25 μM) for 3 days inhibits the growth of the C643, TPC1, BCPAP, and SW1736 cell lines by about 50% at low nanomolar concentrations, while higher concentrations are required to inhibit the growth of the K1 cell line. Treatment with 10 nM or 50 nM Dasatinib results in a 9-22% increase of cells in the G1 population among BCPAP and SW1736 and K1 cells, and a corresponding 7-18% decrease in the percentage of cells in the S phase. [4]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
M07ep210NYDuPIxmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWG3NkBpMXvEUXNQM4f0fWlEPTB;MD6wNFAxPyEQvF2=NV:zV3VXOTd7NU[wPFA>
K562M1z5cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{XEPVczKGh?MmjmSG1UVw>?MkjoTWM2OD1yLkCwNUDPxE1?M3vWO|E4QTV4MEiw
M07eMUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoLDO|IhcA>?M1TXZmROW09?NXP4XHhXUUN3ME2wMlAxOTJizszNMkHMNVc6PTZyOEC=
ALL3NFT1ZWNEgXSxdH;4bYMhSXO|YYm=MUGwMlHPxE1?NUPYS3dFPzJiaB?=MV3EUXNQNFTXXpNKSzVyPUCuNFAxPCEQvF2=M2LnflE6QDh7NUSw
CMLNXqwcHpvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4PKS|IxKG2rbh?=Mnn6SG1UVw>?NFK1bVBKSzVyPUCuNFAyKM7:TR?=NH\ybG0yQTJzOUCxOi=>
BA/F3NUH0ZmZyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEfSVog4OiCqNYP6U4VqTE2VTx?=MVLJR|UxRTZwNUi5JO69VQ>?Mlr0NlMxQDh4NES=
BA/F3MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUi3NkBpM4TZNWROW09?MorsTY5lfWOnczDhcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IH3veZNmKEKDL1[zJINmdGy|IHX4dJJme3OrbnegRoNzNUGkbDDNN|UyXCCvdYThcpQhf2m2aDDJR|UxKG:oIECuNFAxQDQQvF2=M2W4R|I{ODh6NkS0
BA/F3MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHXBNYY4OiCqNWHObFg4TE2VTx?=MUHJcoR2[2W|IHHueIlxem:uaX\ldoF1cX[nIHHjeIl3cXS7IHHnZYlve3RibX;1d4UhSkFxRkOgZ4VtdHNiZYjwdoV{e2mwZzD3bYxlKHS7cHWgRoNzNUGkbDD3bZRpKEmFNUCgc4YhOC5yMES1{txOMYGyN|A5QDZ2NB?=
BA/F3NFjWNmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnP5O|IhcA>?NVK3N2NtTE2VTx?=MorhTY5lfWOnczDhcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IH3veZNmKEKDL1[zJINmdGy|IHX4dJJme3OrbnegRoNzNUGkbDDUN|E2USCvdYThcpQhf2m2aDDJR|UxKG:oIEGuO|E1|ryPNFq4S2czOzB6OE[0OC=>
BA/F3NVvKWZhbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYPPepJnPzJiaB?=NF72VIdFVVORNXHMVI9pUW6mdXPld{BkgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBDSS:IMzDj[YxteyCneIDy[ZN{cW6pIFLDVk1CSkxiRkS4OnMhdXW2YX70JIF{e2W|c3XkJIF{KGe{b4f0bEBKdmirYnn0bY9vKHerdHigTWM2OCCxZjCwMlAxODoQvF2=NXrw[pRMOjN|MEG3NFM>
BA/F3NHLSZXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2Gz[VczKGh?MmrsSG1UVw>?MXnJcoR2[2W|IHP5eI91d3irY3n0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4PpcochSkOULVHCUEBGOjV3SzDteZRidnRiYYPz[ZN{\WRiYYOg[5Jwf3SqIFnubIljcXSrb36ge4l1cCCLQ{WwJI9nKDBwMECzNu69VQ>?MkXtNlM{ODF5MEO=
BA/F3MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4ezflczKGh?NYKzW|hLTE2VTx?=MojzTY5lfWOnczDjfZRwfG:6aXPpeJkh[WejaX7zeEBud3W|ZTDCRU9HOyClZXzsd{BmgHC{ZYPzbY5oKEKFUj3BRmwhTzJ3MFWgcZV1[W62IHHzd4V{e2WmIHHzJIdzd3e2aDDJcohq[mm2aX;uJJdqfGhiSVO1NEBw\iByLkCwOVHPxE1?Mn\ZNlM{ODF5MEO=
BA/F3M2HIemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWm3NkBpM4DoVmROW09?MoLETY5lfWOnczDjfZRwfG:6aXPpeJkh[WejaX7zeEBud3W|ZTDCRU9HOyClZXzsd{BmgHC{ZYPzbY5oKEKFUj3BRmwhWTJ3MligcZV1[W62IHHzd4V{e2WmIHHzJIdzd3e2aDDJcohq[mm2aX;uJJdqfGhiSVO1NEBw\iByLkCwPO69VQ>?M1nBVFI{OzBzN{Cz
BA/F3M2GzV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXzlRnpoPzJiaB?=NYHkVFNYTE2VTx?=NHLTfWRKdmS3Y3XzJIN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCN0Z|IHPlcIx{KGW6cILld5NqdmdiQlPSMWFDVCCHM{W5WkBufXSjboSgZZN{\XO|ZXSgZZMh\3Kxd4ToJGlvcGmkaYTpc44hf2m2aDDJR|UxKG:oIECuNFAyO87:TR?=MX[yN|MxOTdyMx?=
BA/F3M1nrfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NF;le3c4OiCqMoHZSG1UVw>?NY\KfVFCUW6mdXPld{BkgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBDSS:IMzDj[YxteyCneIDy[ZN{cW6pIIfpcIQhfHmyZTDCR3IuSUKOIHHzd4V{e2WmIHHzJIdzd3e2aDDJcohq[mm2aX;uJJdqfGhiSVO1NEBw\iByLkCwNVnPxE1?NVHoXVJDOjN|MEG3NFM>
BA/F3MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHK1e484OiCqMWfEUXNQM1H6SWlv\HWlZYOgZ5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmEwTjNiY3XscJMh\XiycnXzd4lv\yCEQ2KtRWJNKFl{NUPIJI12fGGwdDDhd5Nme3OnZDDhd{Boem:5dHigTY5pcWKrdHnvckB4cXSqIFnDOVAhd2ZiMD6wNFI{|ryPNIPwcY0zOzNyMUewNy=>
BA/F3MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoLEO|IhcA>?MoHhSG1UVw>?MnntTY5lfWOnczDjfZRwfG:6aXPpeJkh[WejaX7zeEBud3W|ZTDCRU9HOyClZXzsd{BmgHC{ZYPzbY5oKEKFUj3BRmwhXDNzNVmgcZV1[W62IHHzd4V{e2WmIHHzJIdzd3e2aDDJcohq[mm2aX;uJJdqfGhiSVO1NEBw\iB|LkdOwG0>NILON|czOzNyMUewNy=>
BA/F3M3PJfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3LtelczKGh?NWTuR3BCTE2VTx?=NUXieVZSUW6mdXPld{BkgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBDSS:IMzDj[YxteyCjc4Pld5Nm\CCjczDndo94fGhiSX7obYJqfGmxbjD3bZRpKEmFNUCgc4YhOi53zszNM3rrWFI{OzBzN{Cz
T cellNFezcnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4nqd|czKGh?MofrSG1UVw>?M3flcmlvcGmkaYTzJIFvfGliQ1SzMUBidmRiYX70bUBETDJ6LXnu[JVk\WRiVDDj[YxtKHC{b3zp[oVz[XSrb36ge4l1cCCLQ{WwJI9nKDBwMECz{txONX7mVlJCOTdzNUS1NVI>
WiDrMlq4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4P4blczKGh?MmrOSG1UVw>?M2fEWmlEPTB;MD6wOVIh|ryPM2\pcFE2PjF3NUGy
PC3Mmn3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnHUO|IhcA>?MYXEUXNQMnnoTWM2OD1yLkCwPVQh|ryPM2HGPVE2PjF3NUGy
MDA-MB-231M1z4Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWPpV|FlPzJiaB?=NXH5TG1qTE2VTx?=MnXyTWM2OD1yLkCxNkDPxE1?NH;WdJcyPTZzNUWxNi=>
Hs578TNVXlSFk2S3m2b4TvfIlkKEG|c3H5NV7pelhxPzJiaB?=NV;1ZWpSTE2VTx?=NH;4WoFIUTVyPUCuNFMh|ryPMnnSNlQxOTV|Mke=
HMECMnjqR5l1d3SxeHnjJGF{e2G7MVu3NkBpNVHMco04TE2VTx?=MkPhS2k2OD1zLkig{txOM{LhXlI1ODF3M{K3
DU145NIHyUotEgXSxdH;4bYMhSXO|YYm=Mn7uO|IhcA>?MWLEUXNQM4HyeWdKPTB;MD6xOkDPxE1?NInRUZEzPDBzNUOyOy=>
U251MW\DfZRwfG:6aXOgRZN{[Xl?NX;zVlRjPzJiaB?=Mly5SG1UVw>?NHLme4ZIUTVyPUKuPFEh|ryPNInyZpczPDBzNUOyOy=>
NCI60MnXER5l1d3SxeHnjJGF{e2G7NV31VWFNPzJiaB?=M4TCUGROW09?NGXacJhIUTVyPUWuO{DPxE1?NVfrb4x2OjRyMUWzNlc>
MALME-3MMni0R5l1d3SxeHnjJGF{e2G7MX63NkBpMojZSG1UVw>?NHnGboNIUTVyPU[uOlEh|ryPM3PoXFI1ODF3M{K3
KM12NGX2VWREgXSxdH;4bYMhSXO|YYm=NH3pNlg4OiCqNGH2TmpFVVORNFv0XI5IUTVyPUeuOFQh|ryPNUnRVo1COjRyMUWzNlc>
SW620Ml\PR5l1d3SxeHnjJGF{e2G7Mn30O|IhcA>?MX;EUXNQM2jj[2dKPTB;OD60N{DPxE1?MUWyOFAyPTN{Nx?=
RXF 393NLMkXGR5l1d3SxeHnjJGF{e2G7NYDqNnVIPCCmYYnzNGLRNGpFVVORM{Hnb2lEPTB;MD6wNlE4KM7:TR?=Mn3NNlMzPTNyN{S=
LXFA 983LM4\JZmN6fG:2b4jpZ{BCe3OjeR?=NUjGdGVvPCCmYYnzM13ROWROW09?NUPIPIY2UUN3ME2wMlA2PjVizszNMWSyN|I2OzB5NB?=
PRXF DU145NXryS5ZtS3m2b4TvfIlkKEG|c3H5MWe0JIRigXN?NIjSSmtFVVORMWHJR|UxRTBwME[yN{DPxE1?M2PRSlI{OjV|MEe0
PAXF 1657LM4PWNmN6fG:2b4jpZ{BCe3OjeR?=MofHOEBl[Xm|Mly2SG1UVw>?MWrJR|UxRTBwMUKxJO69VQ>?NWnHbmQ1OjN{NUOwO|Q>
CXF 1103LMVfDfZRwfG:6aXOgRZN{[Xl?MYi0JIRigXN?NWfFSFFxTE2VTx?=MXLJR|UxRTRwM{[g{txOMonENlMzPTNyN{S=
GXF251LMkS2R5l1d3SxeHnjJGF{e2G7MmDxOEBl[Xm|MmPkSG1UVw>?NUXJb|BOUUN3ME2yMlI2KM7:TR?=M2[2RlI{OjV|MEe0
NCI-H23MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWS5[m1kPzJiaB?=MkHVSG1UVw>?MV\JR|UxRTJwMkeg{txOMnfRNlM2OjFyMkC=
HCT116NH;TU5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVK3NkBpMUPEUXNQMlHUTWM2OD1{LkOg{txONFXPeIwzOzV{MUCyNC=>
MCF7MnX3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmLHO|IhcA>?NIftXplFVVORMXTJR|UxRTJwNUeg{txOM{n3OFI{PTJzMEKw
NCI-H460M3TWPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUi3NkBpMVvEUXNQM1HlSGlEPTB;OD65PUDPxE1?NV;XeJdCOjN3MkGwNlA>
DLD1MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVS3NkBpNXfxWWw6TE2VTx?=M{\a[GlEPTB;ND62JO69VQ>?NYHQ[VB5OjN3Nke5OlA>
NCI-H661M2\0[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYn5WmRXPzJiaB?=MVXEUXNQNHvZfVRKSzVyPUeuPEDPxE1?MnXONlM2Pjd7NkC=
A549NW\jPVhqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXjweGQxPzJiaB?=M{XhNmROW09?MXPJR|UxRThwMjFOwG0>Mni3NlM2Pjd7NkC=
U937NVPXPZhCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWq0e2VDPzJiaB?=MW\EUXNQMkGzTWM2OD1zMj6yJO69VQ>?NFTvU5AzOzV4N{m2NC=>
HEK293NFTLNG5HfW6ldHnvckBCe3OjeR?=MXexNOKh|ryPNYr0O5I6TE2VTx?=NEXiOlBKdmS3Y3XzJIJqdmSrbnegZYZncW6rdImgeI8hcHWvYX6g[pVtdC2uZX7neIghUGm|LYTh[4dm\CCPeYSxJItqdmG|ZTDlfJBz\XO|ZXSgbY4hUEWNMkmzJINmdGy|IIfpeIghUUN3MDDv[kAxNjB4M988US=>MWmyNlc4ODZzMB?=
HUVECMnzIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MY[wMlE2yqEQvF2=NH;aOnc4OiCqNFHkZ41FVVORNXviXYxGUW6mdXPld{BidnSrYX7nbY9o\W6rYzDhZ5Rqfmm2eTDpckBJXV[HQzDjc{1kfWy2dYLl[EB4cXSqII\hd4N2dGG{IIPtc491cCCvdYPjcIUh[2WubIOgZZN{\XO|ZXSgZZMhUW6qaXLpeIlwdiCxZjDj[YxtKGe{b4f0bEBifCByLkG1JJVONYn2WHVCOjJ6NUO5PVM>
HUVECNXTQeWd1TnWwY4Tpc44hSXO|YYm=M363R|E2yqEQvF2=M3T6R|czKGh?MXTEUXNQNH;aXFlKdmS3Y3XzJIFvfGmjbnfpc4dmdmmlIHHjeIl3cXS7IHnuJGhWXkWFIHPvMYN2dHS3cnXkJJdqfGhidnHzZ5Vt[XJic33vc5RpKG23c3Ps[UBk\WyuczDhd5Nme3OnZDDhd{BKdmirYnn0bY9vKG:oIH7leJdwemtiZn;ycYF1cW:wIHH0JFEvQCC2bzCxOUB2VQ>?NX7QU2tGOjJ6NUO5PVM>
Plasmodium falciparumNYexSZN7TnWwY4Tpc44hSXO|YYm=Ml[3NVDDqM7:TR?=M3n6[|E2KG2rbh?=MnX5SG1UVw>?MoDsTY5pcWKrdIOgVIxie22xZHn1cUBn[WylaYDhdpVuKHC{b3zp[oVz[XSrb36gZpkhcW6qaXLpeIlv\yC2aHWgSpVv[3Srb36gc4YhWG[FRGDLNUBxem:2ZXnuJJdqfGhiSVO1NEBw\iBzLkG3{txONXvyVHVZOjR3NUCzN|A>
PC3MXzGeY5kfGmxbjDBd5NigQ>?NGLDUHcxNjFizszNMl:xOUBpNGDKd3NFVVORMmfCTY5pcWKrdIOgbJVu[W5iUFOzJINmdGxiYXTo[ZNqd25iYYSgNVAxKG6PMkDXNVk1PjJ7N{W=
DU145Mn3mSpVv[3Srb36gRZN{[Xl?NX\XXlBbOC5zIN88US=>NYfLcXlsPSCqMkO1SG1UVw>?M2TLWGlvcGmkaYTzJIh2dWGwIFTVNVQ2KGOnbHygZYRp\XOrb36gZZQhOTByIH7NMUmxPVQ3Ojl5NR?=
PC3NWDVN5N[U2mwYYPlJGF{e2G7NIDhbJcxNjFizszNNUTTSYVGPSCqNXLCN3hJTE2VTx?=MXjJcohq[mm2czDjV5JkKGmwIHj1cYFvKFCFMzDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gc4YheGixc4Doc5J6dGG2ZXSgV5JkKFl2MU[gcIV3\WxiYYSgNVAxKG6PNFrwTWgyQTR4Mkm3OS=>
DU145MnjsT4lv[XOnIFHzd4F6MVuwMlEh|ryPNW\rNJNiPSCqNWP6V3FzTE2VTx?=MVPJcohq[mm2czDjV5JkKGmwIHj1cYFvKESXMUS1JINmdGy|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBw\iCyaH;zdIhwenmuYYTl[EBUemNiWUSxOkBt\X[nbDDheEAyODBibl2=NWTBWmpuOTl2NkK5O|U>
PC3NVLw[IxnU2mwYYPlJGF{e2G7MYiwMlEh|ryPNWTqSWtUPSCqMXjEUXNQNXPs[ldzUW6qaXLpeJMh[1O{YzDpckBpfW2jbjDQR|Mh[2WubIOgZZN{\XO|ZXSgZZMhemWmdXP0bY9vKG:oIIDoc5NxcG:{eXzheIVlKE[DSzDZOVc3N1l3N{egcIV3\WxiYYSgNVAxKG6PM2rGSFE6PDZ{OUe1
DU145MlLmT4lv[XOnIFHzd4F6MVmwMlEh|ryPMUW1JIg>NGfHbHlFVVORMojsTY5pcWKrdIOgZ3Nz[yCrbjDoeY1idiCGVUG0OUBk\WyuczDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hd2ZicHjvd5Bpd3K7bHH0[YQhTkGNIGm1O|YwYTV5NzDs[ZZmdCCjdDCxNFAhdk1?NV;TfpNSOTl2NkK5O|U>
Huh7NWjP[oloSW62aY\pdoFtKEG|c3H5MXeyMlUh|ryPNGW1UY81KGSjeYO=NWmwRWdZTE2VTx?=M2jL[2lvcGmkaYTzJJZqemGuIIPwdoVi\CCrbjDE[Y5ofWVidnnyeZMucW6oZXP0[YQhcHWvYX6gTJVpPyClZXzsd{Bie3Onc4Pl[EBieyCjY3P1cZVt[XSrb36gc4Yhfmm{YXyg[Y53\WyxcHWgdJJwfGWrbjD3bZRpcW5icHXybY52[2ynYYKgdoVocW:wIHH0JFIvPSC3TR?=M1K3dVE4OzZyNke2
C6/36M3\0Z2FvfGm4aYLhcEBCe3OjeR?=MkHENk42KM7:TR?=MX20JIRigXN?MXzEUXNQNIWzTllKdmirYnn0d{B3cXKjbDDzdJJm[WRiaX6gSIVv\3WnII\pdpV{NWmwZnXjeIVlKGG|aXHuJJRq\2W{IH3vd5F2cXSxIFO2M|M3KGOnbHzzJIF{e2W|c3XkJIF{KGGlY4XteYxifGmxbjDv[kB3cXKjbDDlcpZmdG:yZTDwdo91\WmwIIfpeIhqdiCyZYLpcpVkdGWjcjDy[Ydqd25iYYSgNk42KHWPMlqxNVc{PjB4N{[=
U937NGnLSFNHfW6ldHnvckBCe3OjeR?=M4PRUlEh|ryPM2LZ[lEhcA>?M1jCWGROW09?NWLtV25nWmWmdXPld{Bj[XOjbDDUUmZidHCqYTDy[Yxm[XOnIHnuJIh2dWGwIGW5N|ch[2WubIO=NXW4emN{OTd4OESwPVk>
U937M3;JdGZ2dmO2aX;uJGF{e2G7NXn1WJBIOSEQvF2=MonKNUBpNYWxUmtDTE2VTx?=Ml\NVoVlfWOnczDMVHMucW6mdXPl[EBVVk[jbIDoZUBz\WynYYPlJIlvKGi3bXHuJHU6OzdiY3XscJM>MlvGNVc3QDRyOUm=
murine mast cellNWT6TmgzTnWwY4Tpc44hSXO|YYm=NFfaTJUyKM7:TR?=Mof3NlQhcA>?MXTEUXNQMojjTY5pcWKrdIOgZY51cWenbj3pcoR2[2WmIFnMOkB{\WO{ZYTpc44hcW5iSXfFJJBzcW2nZDDtc5V{\SCvYYP0JINmdGy|IHH0JFEhfU1?NYLaZolKOTd4OESwPVk>
BV-173NH3PNIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUDmend[UUN3ME2wMlAxODByMEGwPUDPxE1?NWr4[GZPW0GQR1XS
K-562Mn73S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoXlTWM2OD1yLkCwNFAxODJ4NjFOwG0>NHvOUZpUSU6JRWK=
BL-70MoH5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnLWTWM2OD1yLkCwNFAxODh{MjFOwG0>M1nZbnNCVkeHUh?=
EM-2NX3IOGl1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4[w[mlEPTB;MD6wNFAxODFyODFOwG0>M2\LcHNCVkeHUh?=
LAMA-84NHvSUWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2roRWlEPTB;MD6wNFAxODN{MTFOwG0>NVrn[YFGW0GQR1XS
MEG-01M4W2Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4f6cWlEPTB;MD6wNFAxODl6IN88US=>M3PucnNCVkeHUh?=
EoL-1-cellMl;FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkjkTWM2OD1yLkCwNFAyOzFizszNMlLmV2FPT0WU
CTV-1Moe0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MX7JR|UxRTBwMECwNFQxPCEQvF2=NHzROoxUSU6JRWK=
TE-15MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVTGWVB6UUN3ME2wMlAxPTh7IN88US=>NFr2c4tUSU6JRWK=
NOS-1MmXJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NH7kfIVKSzVyPUCuNFA3OTNizszNM4fqb3NCVkeHUh?=
D-336MGMkPhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUjQeGdEUUN3ME2wMlAxPjNizszNMY\TRW5ITVJ?
LB1047-RCCMVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NF3xc|ZKSzVyPUCuNFA6QDlizszNM{jtdHNCVkeHUh?=
LB996-RCCMoHZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NH:4NlBKSzVyPUCuNFA6QTFizszNNXjmeHV1W0GQR1XS
SW982Ml;BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NV;6ZZZwUUN3ME2wMlAyOTF3IN88US=>M1zYfHNCVkeHUh?=
TK10NWTCPIcxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWHvfGZJUUN3ME2wMlAyOTd2IN88US=>MlX1V2FPT0WU
A704M2H4Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnTnTWM2OD1yLkCxOFkyKM7:TR?=M4j2WXNCVkeHUh?=
TE-8M3v5NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3nXVmlEPTB;MD6wNVU4PiEQvF2=MUHTRW5ITVJ?
DOHH-2MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVK1[HlkUUN3ME2wMlAyPzF7IN88US=>MWHTRW5ITVJ?
HOP-62M{XuR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1zMS2lEPTB;MD6wNVg{PCEQvF2=MWLTRW5ITVJ?
TE-12M2PoSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlTwTWM2OD1yLkCxPFYyKM7:TR?=NHzYW4RUSU6JRWK=
KGNNXvScHZLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWe1WHlHUUN3ME2wMlAyQTR{IN88US=>MYPTRW5ITVJ?
NCI-H1648MmjOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{W2WmlEPTB;MD6wNlAyOSEQvF2=NX7IR|ZKW0GQR1XS
OS-RC-2NInVN5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2ixSWlEPTB;MD6wNlA{KM7:TR?=M2[1UnNCVkeHUh?=
GB-1M2Ptbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{O5VmlEPTB;MD6wNlE2PyEQvF2=M4\xe3NCVkeHUh?=
RXF393NY\6NFFuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M37uSWlEPTB;MD6wNlM2PyEQvF2=NFXGcXRUSU6JRWK=
LC-2-adNHS1[ZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3nnSWlEPTB;MD6wNlU5PiEQvF2=M1\TV3NCVkeHUh?=
KS-1Ml;YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXjWOYdkUUN3ME2wMlAzPzNizszNNWfVO211W0GQR1XS
ETK-1M2LYXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXLJR|UxRTBwMEK4N|Ih|ryPM{XYVnNCVkeHUh?=
SW954M2\CN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUj1[2hnUUN3ME2wMlAzQTJ5IN88US=>Ml7OV2FPT0WU
BeckerNEXMVodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYfJR|UxRTBwMEOwNFMh|ryPNXrie3RrW0GQR1XS
MZ1-PCMn7zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWHJR|UxRTBwMEOxNVkh|ryPNX3KWI06W0GQR1XS
ES6MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3HjSmlEPTB;MD6wN|E6OyEQvF2=MYPTRW5ITVJ?
KURAMOCHINWO2[mwyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NV3qW5BDUUN3ME2wMlA{PDh5IN88US=>M4XiV3NCVkeHUh?=
CGTH-W-1MkXvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEG3b|RKSzVyPUCuNFM2PDhizszNM2qxZ3NCVkeHUh?=
VA-ES-BJMlraS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MU\JR|UxRTBwMEO5NFIh|ryPM2nWUHNCVkeHUh?=
LXF-289NVjnco5YT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NELaOlRKSzVyPUCuNFM6PTZizszNNXPq[JQ5W0GQR1XS
MPP-89NXfXdFVZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYjJR|UxRTBwMESwOFkh|ryPMWTTRW5ITVJ?
SW872MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnLBTWM2OD1yLkC0NVYyKM7:TR?=NGnTcpBUSU6JRWK=
SNB75NFvyUYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NH\3VnVKSzVyPUCuNFQ1OzVizszNNXf5eYVRW0GQR1XS
PSN1MmWyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnuwTWM2OD1yLkC0OFc1KM7:TR?=NFmxW4JUSU6JRWK=
LB831-BLCMWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnGwTWM2OD1yLkC0OlA6KM7:TR?=M4\ac3NCVkeHUh?=
MFH-inoNH3M[I9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlXwTWM2OD1yLkC0O|I1KM7:TR?=M2XKV3NCVkeHUh?=
TGBC24TKBNHrPeWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4Pz[2lEPTB;MD6wOFc3OSEQvF2=MmXsV2FPT0WU
A388M4PH[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGiyOGZKSzVyPUCuNFUxQTVizszNMUnTRW5ITVJ?
BB30-HNCMlnLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIPvNFNKSzVyPUCuNFU1OzdizszNNGjZc3FUSU6JRWK=
GI-ME-NMYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MX3JR|UxRTBwME[xNVgh|ryPM4m2WXNCVkeHUh?=
TGBC1TKBMUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MY\JR|UxRTBwME[xOlQh|ryPM1W4[HNCVkeHUh?=
TE-10M2HxV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHThd2xKSzVyPUCuNFY{PTdizszNNXnuepdmW0GQR1XS
A498M2jsfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVjY[YV2UUN3ME2wMlA4Ojh2IN88US=>M2i0SHNCVkeHUh?=
TE-11NYnJcmNCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUfZZ3BHUUN3ME2wMlA4QDV6IN88US=>MmLUV2FPT0WU
BB65-RCCM{HLbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFXFUmZKSzVyPUCuNFgzOjdizszNMlf5V2FPT0WU
C2BBe1MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGn5VFVKSzVyPUCuNFg{ODhizszNNVfN[pYxW0GQR1XS
NCI-H747MkHBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MU\JR|UxRTBwMEizOlIh|ryPM1fWTnNCVkeHUh?=
IST-MES1MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1H6bWlEPTB;MD6wPFU2OiEQvF2=MWLTRW5ITVJ?
KALS-1NH7yXoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MonCTWM2OD1yLkC5OFkh|ryPNXvaPG13W0GQR1XS
GCIYM3Ozemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXH4flI5UUN3ME2wMlA6PjV4IN88US=>MnXQV2FPT0WU
RL95-2NVP2TYIzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVPjdXZWUUN3ME2wMlExOzhizszNNEPzfolUSU6JRWK=
TE-1NWTlXIl[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXHJR|UxRTBwMUC1OEDPxE1?M{T5bHNCVkeHUh?=
NCI-H1355M4HZNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnfVTWM2OD1yLkGxNFI5KM7:TR?=MkjuV2FPT0WU
SW962M4n0XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFj0e4dKSzVyPUCuNVEzQTJizszNNILuWZNUSU6JRWK=
KLEMXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2LuNGlEPTB;MD6xNVMyPyEQvF2=M2TjNHNCVkeHUh?=
MC116MlPrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVvJR|UxRTBwMUG0NUDPxE1?NWrHdVlxW0GQR1XS
NMC-G1NUezTI5mT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3myU2lEPTB;MD6xNVYxPiEQvF2=MVjTRW5ITVJ?
KU812M2\sXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWnJR|UxRTBwMUG4PFMh|ryPM1zVSXNCVkeHUh?=
COLO-829NVW0cYY5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MV7JR|UxRTBwMUKyNVMh|ryPNVPnTYFvW0GQR1XS
NTERA-S-cl-D1MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVPJR|UxRTBwMUKyPFMh|ryPMlvLV2FPT0WU
IST-MEL1NInMOHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2K0ZmlEPTB;MD6xN|Q2KM7:TR?=MonsV2FPT0WU
MLMAM4rZOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4rObmlEPTB;MD6xOFA{OiEQvF2=MXTTRW5ITVJ?
LS-123NEP3UHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4\QVGlEPTB;MD6xOFA3PCEQvF2=MYXTRW5ITVJ?
LB2518-MELMYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4KzfGlEPTB;MD6xOFE3OiEQvF2=NYnmUphWW0GQR1XS
NB69NXm5bGhQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2\0TGlEPTB;MD6xOFQ{PiEQvF2=M13aenNCVkeHUh?=
8-MG-BANVTqVpcxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmHZTWM2OD1yLkG1OFU5KM7:TR?=MVHTRW5ITVJ?
K5M4n0W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1jBeGlEPTB;MD6xOlQ5QSEQvF2=NYm0ZZdFW0GQR1XS
KINGS-1NGCzNZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{nmfWlEPTB;MD6xOlY3PiEQvF2=MUfTRW5ITVJ?
SF268MlzNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1uxcmlEPTB;MD6xO|QxPCEQvF2=NVfD[nNYW0GQR1XS
PF-382M2TFVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Ml\jTWM2OD1yLkG3Olc5KM7:TR?=M3v6cHNCVkeHUh?=
SH-4NVe2O3FxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGjHdI5KSzVyPUCuNVg1OTNizszNNWDCVY82W0GQR1XS
NALM-6M17Cemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NF[3SmJKSzVyPUCuNVkzQTVizszNNYj2[VJxW0GQR1XS
CP66-MELM130T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGj6VmlKSzVyPUCuNVk2OzFizszNNVP0[nlIW0GQR1XS
697NWjDW3BbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NF\SZoFKSzVyPUCuNVk6QDdizszNNIe3Vo9USU6JRWK=
CP67-MELM3;Xdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVrpfWl3UUN3ME2wMlIxPDh6IN88US=>NYLaXnFIW0GQR1XS
DSH1Mkf2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHLyRZpKSzVyPUCuNlQxODFizszNNFnId41USU6JRWK=
HCE-4M4HHVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NX[xO5MyUUN3ME2wMlI3PDN7IN88US=>NWX5VVgyW0GQR1XS
MZ2-MELNEj1WIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2C2fWlEPTB;MD6yPFU{PyEQvF2=MnnxV2FPT0WU
BL-41MlLrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHjv[FlKSzVyPUCuNlkyOjNizszNMl:5V2FPT0WU
HUTU-80M1m3RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWXod3lEUUN3ME2wMlMyPDJizszNNVPsfoNsW0GQR1XS
LOXIMVINV3vOZhYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmH6TWM2OD1yLkOxOVA{KM7:TR?=NWTPTpNwW0GQR1XS
no-10NFvnVWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXLYO4lQUUN3ME2wMlMyQTNzIN88US=>M1LPR3NCVkeHUh?=
KARPAS-422M1LsXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXXJR|UxRTBwM{O5PVch|ryPM13QfHNCVkeHUh?=
SW684NWPM[phbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHGy[21KSzVyPUCuN|Q6QCEQvF2=NWnrVndTW0GQR1XS
SF126NUnOXll2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1n0fGlEPTB;MD6zOVQyKM7:TR?=MWTTRW5ITVJ?
D-263MGNULJXpQ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NX7j[49LUUN3ME2wMlM3OjJ2IN88US=>MV3TRW5ITVJ?
OVCAR-4MoWzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXr5TpNyUUN3ME2wMlM4PDN|IN88US=>NUjJS49xW0GQR1XS
BB49-HNCM3nKc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{H5emlEPTB;MD6zPFU6QSEQvF2=NHXiVYlUSU6JRWK=
ONS-76NWnudopiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWrJR|UxRTBwNEK5OVEh|ryPMYPTRW5ITVJ?
MZ7-melNVu5c5J6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYizcnRHUUN3ME2wMlQ4QTFzIN88US=>MlmxV2FPT0WU
RCC10RGBNFf4T|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlTiTWM2OD1yLkS5NVEh|ryPM3vwWnNCVkeHUh?=
BOKUMlHGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NX3ybG1XUUN3ME2wMlQ6OTN|IN88US=>NV6zWHJJW0GQR1XS
no-11NFW3OFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3HafWlEPTB;MD61NFIzQCEQvF2=NVjrcHZ6W0GQR1XS
IST-SL2M1vpTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Ml3kTWM2OD1yLkWwN|AzKM7:TR?=MYDTRW5ITVJ?
RKOMmPlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NH7kdodKSzVyPUCuOVI6PjZizszNNVnpcGN6W0GQR1XS
HT-144M3rRfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWXJR|UxRTBwNUO2NFkh|ryPNXTQU2VwW0GQR1XS
NCI-H446NYS3ZopGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGDBdGZKSzVyPUCuOlI4PiEQvF2=NHHkWmJUSU6JRWK=
QIMR-WILMme3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MojiTWM2OD1yLkewOlI6KM7:TR?=MXnTRW5ITVJ?
MHH-PREB-1NFX4W|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M13sNGlEPTB;MD63OFQ3QSEQvF2=M3zFTnNCVkeHUh?=
EW-16MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{izWmlEPTB;MD63OlE4QCEQvF2=M4myRXNCVkeHUh?=
EW-24MnjxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUHJR|UxRTBwN{ixOlUh|ryPMW\TRW5ITVJ?
LB373-MEL-DNYL3N3U1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEHPPXJKSzVyPUCuPFI2ODhizszNNETI[GdUSU6JRWK=
TE-9MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVLsUHZIUUN3ME2wMlg4PTN{IN88US=>NVjB[npEW0GQR1XS
A3-KAWMnv4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmTVTWM2OD1yLkm4OFUzKM7:TR?=MY\TRW5ITVJ?
A101DNF7iXW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGTF[YlKSzVyPUGuNFMxPDNizszNM{GwTnNCVkeHUh?=
OCUB-MNUKwWGJVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXPJR|UxRTFwMES0NVIh|ryPMoT4V2FPT0WU
ES4MlXyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmXFTWM2OD1zLkC1NVQ2KM7:TR?=MXrTRW5ITVJ?
TE-6NGfwfYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4j3OWlEPTB;MT6yNVIzPiEQvF2=NXfGO2tuW0GQR1XS
D-502MGM1jTeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFjmbGpKSzVyPUGuNlM{PzZizszNMYjTRW5ITVJ?
KNS-42M4Hnfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYm1cVdSUUN3ME2xMlI1PDF{IN88US=>MVnTRW5ITVJ?
SNU-C2BMXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWjuOWVzUUN3ME2xMlMxPTh7IN88US=>MnTXV2FPT0WU
NCI-H1838M3TEPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWLQSZFiUUN3ME2xMlMxPzN|IN88US=>M2nhcHNCVkeHUh?=
NKM-1NH\iZpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MX\JR|UxRTFwM{C4OVkh|ryPNIPrOnhUSU6JRWK=
GI-1Mn;wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkD5TWM2OD1zLkO2NlIh|ryPNV\JPGhvW0GQR1XS
NB5NEXFSmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYLJR|UxRTFwM{m4Nlch|ryPMWDTRW5ITVJ?
CAS-1Mn7US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUfJR|UxRTFwNEC5PVIh|ryPNIPt[3JUSU6JRWK=
HCE-TMULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MV\JR|UxRTFwNU[3NVQh|ryPM2q2cXNCVkeHUh?=
SBC-1NHLyOVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVzJR|UxRTFwNUe5PFQh|ryPM3TKdnNCVkeHUh?=
JiyoyeP-2003MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MULJR|UxRTFwN{O0OlYh|ryPM{\tUHNCVkeHUh?=
TE-5MlnyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3jRfGlEPTB;MT63PVE{QSEQvF2=NXn4U|c5W0GQR1XS
CANM3zDTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NU\Rc4hLUUN3ME2xMlgzOjV{IN88US=>MojlV2FPT0WU
SK-UT-1NUnneIdlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MU\JR|UxRTJwMU[2PVMh|ryPNUS2ZYR{W0GQR1XS
JVM-2NEP2R|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlLZTWM2OD1{LkO2Nlg1KM7:TR?=MW\TRW5ITVJ?
LB771-HNCMoHOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVfJR|UxRTJwNUe1OVEh|ryPM3m1TXNCVkeHUh?=
NCCITMVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmnrTWM2OD1{Lki2OlE3KM7:TR?=NIrxSGVUSU6JRWK=
NCI-H2126M3\SR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUK2[mdrUUN3ME2yMlg4PTV{IN88US=>NXu5fpFlW0GQR1XS
Calu-6NF7RWotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXrJR|UxRTNwMEW3OFEh|ryPMl;JV2FPT0WU
SK-LMS-1Mof6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUTJR|UxRTNwMUG4PFYh|ryPNXvRfINxW0GQR1XS
ARH-77MoXGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnrBTWM2OD1|LkS2PVE2KM7:TR?=M1e5UHNCVkeHUh?=
NB17MmHiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MX7JR|UxRTNwNkO4OFch|ryPMlrCV2FPT0WU
A253MnLnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFL6PJFKSzVyPUOuO|MzPDZizszNMXvTRW5ITVJ?
OPM-2MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWXn[3ZzUUN3ME20MlI4Pjh3IN88US=>MWPTRW5ITVJ?
MV-4-11NI\QbnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXTJR|UxRTRwM{[0OVQh|ryPM{D3XnNCVkeHUh?=
SRMV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MULJR|UxRTRwNEm5OVQh|ryPMV;TRW5ITVJ?
KG-1NF7FOVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NELiPWtKSzVyPUSuOlA5PDVizszNMYTTRW5ITVJ?
OCI-AML2NI[yUoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGLPdW5KSzVyPUWuPFYyPTRizszNM{HFVXNCVkeHUh?=
D-247MGNXjub5pDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUnJR|UxRTZwMUK1NVkh|ryPNILWWoVUSU6JRWK=
DJM-1NGTr[VdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYHBT2l2UUN3ME22MlQ5PTV6IN88US=>M3jGbHNCVkeHUh?=
RPMI-6666M2Lobmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVj4NHZsUUN3ME23MlI4ODZ5IN88US=>M{PjTnNCVkeHUh?=
KARPAS-45NGDtT2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXvJR|UxRTdwNUG2O|Eh|ryPMl7iV2FPT0WU
LP-1Ml;SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVvqVoJ1UUN3ME23MlU1Pzh{IN88US=>MXfTRW5ITVJ?
RS4-11NV[y[lFST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2O3fWlEPTB;Nz62OVc5PyEQvF2=MV7TRW5ITVJ?
DU-4475MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXTEd2tjUUN3ME24MlIyPjV{IN88US=>NG\GdJRUSU6JRWK=
MONO-MAC-6M4L5cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlvUTWM2OD16LkK3NFY3KM7:TR?=NVPoc3FIW0GQR1XS
NCI-SNU-16MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3zHTmlEPTB;OD61OlEzQCEQvF2=MlfIV2FPT0WU
SJSA-1Mk\HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVjJR|UxRThwN{K4NFUh|ryPMl\0V2FPT0WU
MMAC-SFNGnhT5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3vjOGlEPTB;OD63PVMxPyEQvF2=M2rYfnNCVkeHUh?=
SK-NEP-1NV7DWoZlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1T1WWlEPTB;OD64PVE2PSEQvF2=MYjTRW5ITVJ?
J-RT3-T3-5MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlSyTWM2OD16Lkm2OVI6KM7:TR?=M{LkbnNCVkeHUh?=
SKM-1NF7UPHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NETPVmtKSzVyPUmuNFE4OzRizszNM4rXdnNCVkeHUh?=
LB2241-RCCMWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1nVPGlEPTB;OT6wNlAyOiEQvF2=M{PTNnNCVkeHUh?=
SIG-M5M1\5SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkOzTWM2OD17LkCyOFk{KM7:TR?=MYfTRW5ITVJ?
EVSA-TM2HWOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXz2UXM3UUN3ME25MlI4Pzl|IN88US=>NHf2cJRUSU6JRWK=
GT3TKBMXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXHJR|UxRTlwM{W1OFYh|ryPNHvXSXJUSU6JRWK=
NB6MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlOyTWM2OD17LkmyNlU6KM7:TR?=NX7zTnIzW0GQR1XS
EHEBMkXUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXnXbHlrUUN3ME2xNE4xPjV4IN88US=>MUHTRW5ITVJ?
HELNVrBOFJvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MofqTWM2OD1zMD60O|c3KM7:TR?=MnPoV2FPT0WU
ALL-PONEDkbZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1q4cGlEPTB;MUCuO|k{QCEQvF2=NELXRpJUSU6JRWK=
TGWMV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mkf6TWM2OD1zMT6yPFI5KM7:TR?=NVzib5dMW0GQR1XS
BC-3NXrFcWt7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3XwN2lEPTB;MUKuNVE{QCEQvF2=NYXIeZZPW0GQR1XS
IA-LMNIrkPYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MX;JR|UxRTF{LkS0OFUh|ryPNXXVTlNWW0GQR1XS
UACC-257Mk\YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnfKTWM2OD1zMj65NVk5KM7:TR?=NXvoWVNMW0GQR1XS
KP-N-YSNF6xN3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXzJR|UxRTF{LkmyPFMh|ryPMnvkV2FPT0WU
RajiMYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGX1XFlKSzVyPUGzMlc1QTdizszNM1fSfXNCVkeHUh?=
SF539NWHJZ4ZNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mm\KTWM2OD1zMz64OVU4KM7:TR?=MUnTRW5ITVJ?
DMS-153NF[5SG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NX:xVVJkUUN3ME2xOE4xODJ6IN88US=>Ml7hV2FPT0WU
L-540NWPMSm11T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NV3uWGV7UUN3ME2xOU4xPjd{IN88US=>NInUOZpUSU6JRWK=
MN-60NHiz[ldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mm\KTWM2OD1zNT6xPVc6KM7:TR?=NWnGRVlPW0GQR1XS
RPMI-8866M2fjU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYLvRnlRUUN3ME2xO{41PDV2IN88US=>NIjtdmRUSU6JRWK=
NCI-H510ANVnnZZZVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIqwVGpKSzVyPUG5MlM6PzNizszNMkfsV2FPT0WU
NB13M3HldGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWXJR|UxRTF7LkS4O|ch|ryPMkXLV2FPT0WU
HAL-01NF;hbIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGHoVlVKSzVyPUG5Mlc2PDNizszNMXfTRW5ITVJ?
NCI-H720NV\mcG9nT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NF\4cGpKSzVyPUKwMlI4OzNizszNNEfRZmdUSU6JRWK=
REHNHj2NVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXvJR|UxRTJyLk[zOVch|ryPMnvNV2FPT0WU
KNS-81-FDNUDSbI57T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVzJR|UxRTJ|LkG0OkDPxE1?NX3BSVA4W0GQR1XS
HC-1M3jSc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmrJTWM2OD1{ND61OVUyKM7:TR?=M1zObnNCVkeHUh?=
NCI-H2141NFjQO|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHnQXmFKSzVyPUK0Mlc4PTRizszNMn7BV2FPT0WU
MOLT-4NW\UfGp5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUHJR|UxRTJ4Lk[3OVMh|ryPNX;NS244W0GQR1XS
OMC-1MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1vYSmlEPTB;MkeuNVQzOiEQvF2=NUTMTXdWW0GQR1XS
LC-1FNFjBTHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlyzTWM2OD1{Nz6zNlQ2KM7:TR?=NEHMVolUSU6JRWK=
NCI-H1304NHTkeGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXrJR|UxRTJ6LkG2Nlgh|ryPNULYb3dHW0GQR1XS
BC-1MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYHJR|UxRTJ6Lk[1NUDPxE1?M2LPdnNCVkeHUh?=
NCI-H64MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVHhPFhHUUN3ME2yPU43OjV|IN88US=>Mn3aV2FPT0WU
MOLT-16NXXBXVRzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHrodJZKSzVyPUK5MlYzQTJizszNM3TQe3NCVkeHUh?=
U-87-MGM{m3SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFj3[mNKSzVyPUOwMlc3PiEQvF2=NF7SOnhUSU6JRWK=
GAKMVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnLsTWM2OD1|MT6yOlg3KM7:TR?=NVe4TFBYW0GQR1XS
ES8NWnpW4FvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3GyVWlEPTB;M{KuNVI2OiEQvF2=NVW1cHFXW0GQR1XS
HCC1599NGTHS3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlnjTWM2OD1|Mj6zN|I2KM7:TR?=Ml\CV2FPT0WU
EB-3MknoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYrJR|UxRTN2LkOxNVch|ryPMUTTRW5ITVJ?
HCC1187NVzqbno5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkfrTWM2OD1|NT64NFUzKM7:TR?=MYLTRW5ITVJ?
SK-PN-DWNF;C[3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGrwWY1KSzVyPUO2MlE6PDNizszNNVO3VGtMW0GQR1XS
JVM-3MmjZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXPCSnM6UUN3ME2zO{4zOzN6IN88US=>NGP0VVNUSU6JRWK=
HCC2157MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1fJU2lEPTB;M{euPVk1PiEQvF2=Ml;WV2FPT0WU
A4-FukNVXuenQxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mm\iTWM2OD1|OD6xNFA6KM7:TR?=NHXtbYpUSU6JRWK=
COR-L279NF3QNFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHPLVZNKSzVyPUSwMlI5PTFizszNM4\IbnNCVkeHUh?=
DELNXjFd|NuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NV;xdVVFUUN3ME20NU46ODh4IN88US=>MV;TRW5ITVJ?
NCI-H1395NH23XotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWfJR|UxRTR{LkCxOlMh|ryPMXXTRW5ITVJ?
MHH-NB-11MlfaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlnJTWM2OD12Mz6wPFE5KM7:TR?=MXHTRW5ITVJ?
NCI-H2107MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmnVTWM2OD12Mz60PFQ3KM7:TR?=NFXqfHNUSU6JRWK=
NEC8MojnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkXWTWM2OD12ND6zN|Yh|ryPMXrTRW5ITVJ?
COLO-684MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4rFfmlEPTB;NE[uNlI2QCEQvF2=NX3vOJI3W0GQR1XS
LS-411NM2nxdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MULJR|UxRTR6LkS3OFgh|ryPNXXaU3RuW0GQR1XS

... Click to View More Cell Line Experimental Data

In vivo Dasatinib reverses splenomegaly in LMP2A/MYC double transgenic mice. Dasatinib specifically prevents colony formation by LMP2A expressing bone marrow B cells and decreased spleen size in the TgE mice. Spleen mass is significantly decreased among Dasatinib treated Tg6/λ-MYC mice when compared to the control group. Dasatinib inhibits lymphadenopathy in LMP2A/MYC double transgenic mice. Dasatinib reverses splenomegaly in Rag1KO mice engrafted with tumor cells from LMP2A/MYC double transgenic mice. Dasatinib therapy inhibits Lyn phosphorylation in B lymphocyte tumors expressing LMP2A. [3]
Features

Protocol(Only for Reference)

Kinase Assay:

[1]

Kinase autophosphorylation assays Kinase assays using wild-type and mutant glutathione S-transferase (GST)-Abl fusion proteins (c-Abl amino acids 220-498) are done. GST-Abl fusion proteins are released from glutathione-Sepharose beads before use; the concentration of ATP is 5 μM. Immediately before use in kinase autophosphorylation and in vitro peptide substrate phosphorylation assays, GST-Abl kinase domain fusion proteins are treated with LAR tyrosine phosphatase. After 1-hour incubation at 30 °C, LAR phosphatase is inactivated by addition of sodium vanadate (1 mM). Immunoblot analysis comparing untreated GST-Abl kinase to dephosphorylated GST-Abl kinase is routinely done using phosphotyrosine-specific antibody 4G10 to confirm complete (>95%) dephosphorylation of tyrosine residues and c-Abl antibody CST 2862 to confirm equal loading of GST-Abl kinase. The Dasatinib concentration range is extended to 1,000 nM for mutant T315I. These same inhibitor concentrations are used for the in vitro peptide substrate phosphorylation assays. The three inhibitors are tested over these same concentration ranges against GST-Src kinase and GST-Lyn kinase.

Cell Assay:

[1]

Cell lines Ba/F3 cell lines
Concentrations ~32 nM
Incubation Time 72 hours
Method

Ba/F3 cell lines are seeded in triplicate and incubated with escalating concentrations of Dasatinib for 72 hours. Proliferation is measured using a methanethiosulfonate-based viability assay. IC50 and IC90 values are reported as the mean of three independent experiments done in quadruplicate. The inhibitor concentration ranges are 0 nM to 32 nM (Dasatinib). The Dasatinib concentration range is extended to 200 nM for mutant T315I.

Animal Study:

[3]

Animal Models EμLMP2A (TgE and Tg6 strains), MYC (λ-MYC), and LMP2A/λ-MYC double transgenic mice (Tg6/λ-MYC)
Formulation DMSO
Dosages 30 mg/kg
Administration Administered via i.p.

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)0.020.151.80.40.0810
Body Surface Area (m2)0.0070.0250.150.050.020.5
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] O'Hare T, et al. Cancer Res. 2005, 65(11), 4500-4505.

[2] Shah NP, et al. Blood, 2006, 108(1), 286-291.

view more

Clinical Trial Information( data from http://clinicaltrials.gov, updated on 2016-07-30)

NCT Number Recruitment Conditions Sponsor
/Collaborators
Start Date Phases
NCT02709083 Not yet recruiting Chronic Myelogenous Leukemia|Chronic Myeloid Leukemia|Leukemia Emory University December 2016 Phase 2
NCT02815059 Not yet recruiting Acute Lymphoblastic Leukemia University of Utah|Janssen, LP August 2016 Phase 1
NCT02819804 Not yet recruiting B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Childhood Acute Lymphoblast  ...more B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Childhood Acute Lymphoblastic Leukemia|Refractory Adult Acute Lymphoblastic Leukemia|Refractory Childhood Acute Lymphoblastic Leukemia Northwestern University|National Cancer Institute (NCI) July 2016 Phase 1
NCT02848131 Recruiting Chronic Kidney Disease Mayo Clinic July 2016 Phase 2
NCT02744768 Not yet recruiting Acute Lymphoblastic Leukemia Gruppo Italiano Malattie EMatologiche dellAdulto June 2016 Phase 2

view more

Chemical Information

Download Dasatinib SDF
Molecular Weight (MW) 488.01
Formula

C22H26ClN7O2S

CAS No. 302962-49-8
Storage 3 years -20℃powder
6 months-80℃in solvent
Synonyms BMS-354825
Solubility (25°C) * In vitro DMSO 98 mg/mL (200.81 mM)
Water <1 mg/mL (<1 mM)
Ethanol <1 mg/mL (<1 mM)
In vivo 4% DMSO+30% PEG 300+5% Tween 80+ddH2O 5mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related Src Products

  • Dasatinib Monohydrate

    Dasatinib Monohydrate is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM, respectively.

  • SU6656

    SU 6656 is a selective Src family kinase inhibitor with IC50 of 280 nM, 20 nM, 130 nM, and 170 nM for Src, Yes, Lyn, and Fyn, respectively.

  • PX-478 2HCl

    PX-478 2HCl is an orally active, and selective hypoxia-inducible factor-1α (HIF-1α) inhibitor. Phase 1.

  • Saracatinib (AZD0530)

    Saracatinib (AZD0530) is a potent Src inhibitor with IC50 of 2.7 nM in cell-free assays, and potent to c-Yes, Fyn, Lyn, Blk, Fgr and Lck; less active for Abl and EGFR (L858R and L861Q). Phase 2/3.

    Features:The 1st Src inhibitor to show inhibition of the Src pathway in human tumor tissue.

  • Bosutinib (SKI-606)

    Bosutinib (SKI-606) is a novel, dual Src/Abl inhibitor with IC50 of 1.2 nM and 1 nM in cell-free assays, respectively.

  • KX2-391

    KX2-391, the first clinical Src inhibitor (peptidomimetic class) that targets the peptide substrate site of Src, with GI50 of 9-60 nM in cancer cell lines. Phase 2.

  • PP1

    PP1 is a potent and selective Src inhibitor for Lck/Fyn with IC50 of 5 nM/ 6 nM.

  • PP2

    PP2, a Src family kinase inhibitor, potently inhibits Lck/Fyn with IC50 of 4 nM/5 nM in cell-free assays, ~100-fold less potent to EGFR, inactive for ZAP-70, JAK2 and PKA.

  • WH-4-023

    WH-4-023 is a potent and orally active Lck/Src inhibitor with IC50 of 2 nM and 6 nM in cell-free assays, respectively.

  • Ibrutinib (PCI-32765)

    Ibrutinib (PCI-32765) is a potent and highly selective Brutons tyrosine kinase (Btk) inhibitor with IC50 of 0.5 nM in cell-free assays, modestly potent to Bmx, CSK, FGR, BRK, HCK, less potent to EGFR, Yes, ErbB2, JAK3, etc.

Recently Viewed Items

Tags: buy Dasatinib | Dasatinib ic50 | Dasatinib price | Dasatinib cost | Dasatinib solubility dmso | Dasatinib purchase | Dasatinib manufacturer | Dasatinib research buy | Dasatinib order | Dasatinib mouse | Dasatinib chemical structure | Dasatinib mw | Dasatinib molecular weight | Dasatinib datasheet | Dasatinib supplier | Dasatinib in vitro | Dasatinib cell line | Dasatinib concentration | Dasatinib nmr
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Contact Us